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Abstract 
Background: Liquid chromatography tandem mass spectrometry (LC-MS/MS) enables specific and sensitive quantification of 
steroids with a high-throughput. Saliva sampling is advantageous for multi-sample profiling over longer periods of time as it is 
non-invasive, cheap, can be carried out at home and does not require the attendance of clinical personnel. We developed a rapid 
LC-MS/MS for the measurement of salivary progesterone, frequently assessed as ovulation marker in patients desiring fertility. 
Methods: Samples (300 µL) were prepared by supported liquid extraction using dichloromethane and were reconstituted in 40% 
methanol. Chromatography was performed using a C8 column with a water/methanol gradient containing 0.1% formic acid and 2 
mmol/L ammonium acetate. Quantification was performed with a Waters TQ-S mass spectrometer. 
Results: Total run time was 5.5 min. The lower limit of quantification was 20 pmol/L (1.2 fmol on column). Inter- and intra-assay 
comparison showed coefficients of variation and bias between measured and nominal concentrations of less than 11%. Mean 
recovery was 91%. Interference with a large set of natural and synthetic steroids was excluded. The assay was successfully 
applied to measure progesterone variation during the menstrual cycle (n=9) and diurnal variations during luteal phase (n=7) in 
regularly cycling women. 
Discussion: We present a novel LC-MS/MS assay for the determination of salivary progesterone with high-throughput potential.  
The applicability of the assay for progesterone profiling during the menstrual cycle is demonstrated.  
Keywords 
Progesterone, saliva, liquid chromatography tandem mass spectrometry 
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Introduction 
Progesterone plays a crucial role in female fertility and reproduction. During the menstrual cycle, 
progesterone levels increase in the luteal phase and the peak in progesterone concentration is a widely 
accepted indicator of ovulation
1
. In female infertility, monitoring of progesterone levels can contribute 
beneficially to the success of assisted and non-assisted reproductive therapies 
2, 3
. Additionally, increased 
production and maintenance of progesterone levels, first by the corpus luteum and then by the placenta, is 
essential for the maintenance of pregnancy and therefore progesterone administration in early pregnancy 
has been investigated as a potential tool to reduce preterm birth risk 
4, 5
.  
In clinical practice, monitoring of progesterone production for the surveillance of luteal and placental 
function requires the collection of multiple samples, repeated over periods of weeks to months, and 
therefore, a simple and cheap sampling technique would be most advantageous to use. The collection of 
saliva, in contrast to the standard medium of blood, is non-invasive and can be performed by the patients 
on their own without the need for attendance of clinical personnel 
6
. Additionally, the concentration in 
saliva represents the free, unbound fraction of the hormone and is thus more likely to reflect the bioactive 
concentrations to which a target tissue is exposed 
7
. Significant correlations between total and free 
progesterone concentrations in plasma and salivary concentrations have been described during pregnancy 
8
. Daily saliva progesterone profiling has proven useful for the diagnosis of luteal phase defects 
9
 and 
salivary progesterone has been suggested as biomarker for preterm birth 
10, 11
. Saliva would therefore 
represent the preferred matrix for multi-sample analysis of progesterone, if a reliable, high-throughput 
assay were available.  
For the measurement of salivary progesterone, a variety of immunoassays have been established since the 
1980s 
12-20
 and several of those are commercially available. However, immunoassays have the 
disadvantage of limited specificity due to cross-reactivity with compounds structurally related to the target 
analyte, which is particularly relevant for steroid analysis considering their large natural variety 
21
. This 
limitation can be overcome by the application of liquid chromatography tandem mass spectrometry (LC-
 5 
MS/MS), which exhibits outstanding specificity and also allows high-throughput, if chromatography 
conditions are chosen carefully 
21, 22
. Additionally, LC-MS/MS has the sensitivity to reliably quantify the 
low levels of steroid hormones present in saliva. Previously described LC-MS/MS assays for salivary 
progesterone had limited potential for the applicability in the routine clinical laboratory due to time-
consuming sample preparation and lengthy run time 
23
, or were using a Salivette devices for sample 
collection 
24
, which can falsify the measurement by unspecific binding of salivary hormones to the 
Salivette swab 
25-27
. Our aim was to develop a direct, rapid LC-MS/MS assay combined with a simple, 
one-step sample preparation for the measurement of progesterone in unstimulated whole saliva, which is 
suitable for routine application. We strictly validated its analytical performance and demonstrated its 
applicability to monitor alteration of progesterone concentrations across the menstrual cycle.     
Materials and methods 
Collection of saliva samples. 
Unstimulated whole saliva was collected by the passive drool technique previously described 
25, 28
. Blood 
contamination of saliva samples may lead to a false increase in saliva steroid levels due to the significantly 
higher levels in blood compared to saliva and needs to be avoided. Participants were therefore asked to 
avoid brushing teeth 2 hours before the sample collection, to avoid eating 1 hour before the sample 
collection and to rinse their mouth with water 10-15 min prior to the collection. Upon arrival at the 
laboratory, blood contamination was excluded visually and samples frozen at -20 °C. Samples were 
thawed, centrifuged at 3,000g for 5-10 min and the clear supernatant was aliquoted and stored at -80 °C 
for analysis. For the measurement of diurnal and menstrual variations of salivary progesterone, volunteers 
were healthy women (n=9, age range 26-39 years) with regular menstrual cycles taking no regular 
medication or oral contraceptives. All participants were asked to collect daily morning samples (between 
awakening and 10.00 a.m.) on days 1-8 (follicular phase) and days 18-24 (luteal phase) of their menstrual 
cycle. Day 1 was defined as the start of the menstrual bleed. The number of samples provided per 
participants was 4-7 for each the luteal and the follicular phase morning sample collection (see Figure 
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2A). The time of collection ranged between 05.30 a.m. and 10.00 a.m. Additionally, participants were 
asked to collect a 7-time point diurnal profile during the luteal phase of the same cycle. Requested time 
points were 07:00, 09:00, 11:00, 13:00, 15:00, 19:00, 23:00. Samples collected within plus and minus 30 
minutes of the requested time were accepted. Only samples from women with a surge of salivary 
progesterone during luteal phase, as determined by the analysis of the daily morning samples, were 
considered for the measurement of the diurnal profile (n=7). All participants provided samples for at least 
five of the time points (see Figure 2B) and all samples have been collected between days 19 and 22. In 
total, the number of samples requested per participant over one cycle was 20.  
The sample collection has been ethically approved by the Science, Technology, Engineering and 
Mathematics Ethical Review Committee of the University of Birmingham (ERN_17-0494); all volunteers 
gave written informed consent prior to sample collection; samples were anonymised and no personal 
identifying information was available at the laboratory. 
 
Sample and standard preparation 
Stock solutions were prepared by dissolving progesterone (Sigma Aldrich, Poole,UK) in ultra-pure 
methanol (Fluka, Poole, UK) and were stored at -20 °C. Two separately-weighed stock solutions of 
progesterone were used to prepare standards (0-10,000 pmol/L) and quality controls (QCs; 100, 7500, 
1500 and 3000 pmol/L) by dilution in phosphate-buffered saline pH 7.4 (Sigma, Poole, UK), 
supplemented with 0.1% (w/v) bovine serum albumin (Sigma, Poole, UK) (PBS/BSA). The standards in 
PBS/BSA were used to prepare a calibration curve. Samples, standards and QCs were prepared in parallel 
by supported liquid extraction (SLE). Therefore, 300 µL sample, standard or QC were pipetted into the 
wells of a 2-mL square well 96-well plate (Porvair, Leatherhead, UK) and 10 µL of approximately 40 
nmol/L progesterone-2,2,4,6,6,17alpha-21,21,21-d9 (CDN isotopes, Quebec, Canada) in methanol was 
added as internal standard (IS) using a multipette. The plate was mixed for 1 min and samples were 
transferred onto the wells of a SLE plate (SLE+, Biotage, Uppsala, Sweden). A vacuum was applied to 
draw the entire sample into the matrix of the SLE plate. A fresh 96-well plate was placed under the SLE 
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plate. Following an incubation of the plate at room temperature for 20 min, 1 mL dichloromethane 
(Chromasolv Plus, Sigma Aldrich, Poole, UK) was pipetted onto each well of the SLE plate and allowed 
to pass through to the collection plate until no residual dichloromethane was visible on the wells. A 
vacuum was subsequently applied for 30 seconds to transfer the remaining solvent into the collection 
plate. The dichloromethane was evaporated to dryness using a Vacmaster 96 (Biotage, Uppsala, Sweden) 
and samples were reconstituted in 40% (v/v) ultra-pure methanol in ultra-pure Milli-Q water (Merck-
Millipore, Hertfordshire, UK). 
Liquid chromatography 
Chromatography was performed on an Acquity ultra high pressure liquid chromatography system (UPLC; 
Waters, Manchester, UK) using a 100 x 3 mm 2.6 µm Kinetex
®
 C8 (Phenomenex, Torrance, USA) 
column at 45 °C. 20 µL of sample was injected. Mobile phase A consisted of distilled Milli-Q water with 
0.1% (v/v) formic acid and 2 mmol/L ammonium acetate, mobile phase B was ultra pure methanol with 
0.1% formic acid and 2 mmol/L ammonium acetate. A linear gradient from 85% to 95 % of mobile phase 
B over three minutes at a flow rate of 0.45 mL/min was applied followed by one minute at 100% B with a 
flow rate of 0.6 mL/min before returning to starting conditions for a further minute.  
Mass spectrometry 
The LC eluate was injected into a XEVO
TM
 TQ-S tandem mass spectrometer (Waters, Manchester, UK), 
which was operated in positive ion mode. The capillary was maintained at 0.5 kV and the source 
temperature was 150 °C. Desolvation temperature and gas flow were 600 °C and 800 L/h. The source off 
set was maintained at 30 V. Cone and collisions energies were 25 V and 18 eV. The transitions for 
progesterone were m/z 314.8 > 97.1 and 314.8 > 109.1 (quantifier and qualifier transitions, respectively). 
The IS D9- progesterone was monitored at the transition m/z 323.8 > 100.1. Multiple reaction monitoring 
mode was used with a dwell time of 0.059 s. MassLynx NT 4.1 software was used for system control and 
the MassLynx TargetLynx programm for data processing. Peak area ratios of analyte and IS, 1/x 
weighting and linear least square regression were used to produce the standard curve.      
 8 
Validation 
We undertook method validation according to accepted guidelines 
29
. 
Ion suppression. Six different saliva samples or distilled water were extracted by SLE as described above. 
Dried extracts were reconstituted in 100 µL of 40% methanol and spiked with 10 μL of progesterone in 
methanol to final concentrations of 800 and 3200 pmol/L. As a background control to determine the signal 
from the non-spiked sample, a corresponding volume of water was added to the reconstituted extract of 
saliva samples or water. Ion suppression was calculated from the peak area of progesterone determined in 
extracts of saliva compared to peak area determined in the extract of water after deducting the respective 
background signal: 100-[(areaH2O-areasaliva)/ areaH2O]*100. 
Recovery. 490 μL of saliva or 50% (v/v) methanol were spiked with 10 μL of a progesterone standard in 
methanol yielding final concentrations of 80, 800 and 3200 pmol/L progesterone and a final methanol 
concentration of 2% in the sample. 5 different saliva samples were tested. As a background control, 10 μL 
of water was added to 490 μL of saliva samples or 50% (v/v) methanol. 300μL of the spiked samples were 
subsequently extracted and analysed as described above. The recovery was calculated from the 
concentrations measured in saliva compared to the concentrations measured in 50% (v/v) methanol 
deducting the respective background control. The presented values for recovery thus include extraction 
efficiency and matrix effects.  
Specificity. Solutions of common endogenous and synthetic steroids were prepared in 50% (v/v) methanol 
in distilled water at supraphysiological concentrations and analysed for interference in the progesterone 
and D9-progesterone channels at the relevant retention time. 21-deoxycortisol, aldosterone, 
androstenedione, corticosterone, cortisol, cortisone, DHEA, dexamethasone, testosterone, and 
pregnenolone were tested to a final concentration of 100 nmol/L.  DHEAS (10 µmol/L), budesonide (232 
nmol/L), fludrocortisone (263 nmol/L), fludrocortisone acetate (234 nmol/L) fluocinolone (243 nmol/L), 
triamcinolone (254 nmol/L), triamcinolone acetonide (230 nmol/L), prednisolone (278 nmol/L) and 
prednisone (279 nmol/L), 17-hydroxyprogesterone (1500 pmol/L), 21-hydroxyprogesterone (1500 
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pmol/L), epitestosterone (0.1 nmol/L), beclomethasone (96 nmol/L), 11-deoxycortisol (172 pmol/L), 
dihydrotestosterone (40 pmol/L), cyproterone acetate (48 nmol/L), levonorgestrel (9.6 μmol/L), 
desogestrel (24 μmol/L), norethisterone (1.2 mmol/L) and ethinylestradiol (34 μmol/L) were also tested. 
These concentrations are all in excess of those that would be expected to be seen in saliva.      
Dilution linearity. Three different saliva samples were spiked with 10,000 pmol/L progesterone and 
serially diluted in six steps with PBS/BSA to 156.25 pmol/L. Samples were collected from men and from 
women on oral contraceptives and thus had negligible progesterone concentrations. Measured 
concentrations were plotted against calculated theoretical concentrations and curves were judged linear if 
the correlation coefficient (R
2
) after linear regression was higher than 0.9900.  
Imprecision and bias. Imprecision was assessed for different concentrations in PBS/BSA- or saliva-based 
samples. The same PBS/BSA QC samples (100, 750, 1500 and 3000 pmol/L) were analysed in ten 
different runs to assess inter-assay imprecision as well as ten times within the same run to determine intra-
assay imprecision. Additionally, saliva samples spiked with three different concentrations (100, 1500, 
3000 pmol/L) were tested for intra-assay imprecision; saliva samples for this experiment were collected 
from men and women taking an oral contraceptive, who have negligible progesterone concentrations.  The 
bias was calculated as percentage deviation between the mean observed and nominal concentrations. The 
percentage coefficient of variation (CV) was calculated as ratio of standard deviation and mean.        
Limit of quantification. Ten replicates of low concentrations of progesterone in PBS/BSA were analysed 
in one assay. The lower limit of quantification (LLOQ) was defined as the concentration for which a CV 
and bias of less than 20% were determined.     
Post-extraction stability. Saliva samples (n=24) were extracted and reconstituted for analysis. The plate 
was measured immediately after extraction, subsequently stored at 4 °C for 72h and the measurement was 
repeated. Percentage bias between the results of the two measurements was calculated.       
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Carry-over. A PBS/BSA sample containing 100,000 pmol/L progesterone was analysed followed by 
sample containing only PBS/BSA. Percentage carry-over of progesterone into the following sample was 
calculated from the progesterone peak area determined for the two samples.   
Results 
Analytical performance 
Progesterone and D9-progesterone had retention times of 1.32 and 1.31 min, respectively, producing 
distinct, identifiable peaks. Extracts of saliva samples showed no interfering peaks when using the 
progesterone quantifier transition of m/z 314.8 > 97.1 (qualifier transition 314.8 > 109.1) (Figure 1). Total 
run time was 5.5 min from injection to injection. All validation criteria are summarized in Table 1. The 
mean peak area of progesterone spiked into a reconstituted extract of saliva compared to the spiked extract 
of water was 93.2±8.1% (n=6 for two concentrations) indicating no significant ion suppression by matrix 
compounds. Thereby, the percentage signal for different saliva samples ranged between 79.6% and 110% 
for 800 pmol/L and between 80.3% and 98.6% for 3200 pmol/L demonstrating no significant differences 
between saliva samples from different individuals. The mean recoveries were 92.4±3.1%, 89.9±2.7% and 
90.6±2.8% after the addition of 80, 800 and 3200 pmol/L progesterone to saliva (n=5), respectively. No 
interference with a variety of natural and synthetic steroids with structural similarity to progesterone was 
observed. A Standard curve was obtained by plotting the progesterone/D9-progesterone peak area ratio 
against the nominal progesterone concentrations. The curve was linear over the standard range (0-10,000 
pmol/L), reproducible between assays and showed correlation with the assigned concentrations with R
2
 
values >0.99. Serial dilutions of saliva samples after the addition of 10,000 pmol/L progesterone with 
PBS/BSA showed linearity with a mean R
2
 of 0.997±0.001 (n=3), when the measured concentrations were 
plotted against the calculated, theoretical concentrations. However, a bias between measured and 
theoretical concentrations of <40% was observed. 
Inter-assay imprecision assessment for PBS/BSA-based QCs at concentrations of 100, 750, 1500 and 3000 
pmol/L gave a bias of 10.9, -0.8, 5.7 and 5.0%, respectively, and a CV of 10.5, 3.2, 9.9, 3.2%, respectively 
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(n=10). In an intra-assay experiment for the PBS/BSA-based QCs at the same concentrations a respective 
bias of 3.4, 3.6, 6.9 and 8.6% and respective CVs of 11.4, 3.4, 2.6 and 5.1% were determined (n=10 for 
100 and 1500 pmol/L; n=9 for 3000 pmol/L). The analysis of saliva spiked with 100, 1500 and 3000 
pmol/L progesterone showed an intra-assay CV of 9.3, 1.7 and 9.3%, respectively. The LLOQ was 
determined as 20 pmol/L, which corresponds to 0.4 pg or 1.2 fmol on the column, giving a bias of 11.5% 
and a CV of 6.8% (n=10), which is below the defined cut-off of 20%. After reconstitution in 40% (v/v) 
methanol the extract was stable for at least 72h at 4°C. The percentage bias between the results before and 
after the storage was between -1.9 and 5.4%, which is below the inter-assay variation. The percentage 
carry-over of progesterone from a sample containing 100,000 pmol/L to the following blank sample was 
less than 0.38%.       
Salivary progesterone levels during the menstrual cycle  
We have applied the assay for preliminary investigations of variations of morning salivary progesterone 
levels over the menstrual cycle (n=9) and of diurnal variations during luteal phase (n=7). Participating 
women were aged 26-39 and had a regular menstrual cycle. Saliva samples were collected each morning 
before 10:00 a.m. on days 1-7 and days 18-24 (luteal phase) of the cycle. During days 1-7, for all except 
four samples (collected by three different participants) levels were below the LLOQ (Figure 2A). Seven 
out of nine participants subsequently showed an increase of salivary progesterone from day 18 onwards 
and levels remained elevated for several days. Maximum concentration reached by the individual 
participants ranged between 155 and 526 pmol/L. For four out of seven women with an increase of 
salivary progesterone during luteal phase levels were going down towards baseline again on day 24 with 
two of them reaching levels below the LLOQ. For two participants levels of morning salivary 
progesterone remained below the LLOQ for the entire time monitored (Figure 2A).  
Additionally, diurnal profiles composed of seven time points (Figure 2B) during luteal phase were 
established for seven women who showed the characteristic luteal phase surge of progesterone. A 
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tendency for an increase over the morning hours after awakening followed by a decrease in the afternoon 
can be observed.    
Discussion 
We have developed a novel direct assay for rapid high-throughput measurement of salivary progesterone 
by LC-MS/MS. The single step extraction using SLE in combination with the short chromatography 
render the assay suitable for routine applications with appropriate throughput as opposed to previously 
published assays 
23
. This is essential for multi-sample measurements that are required to monitor 
progesterone levels during pregnancy and patients undergoing diagnostic assessment or therapy for 
desired fertility. The use of saliva as matrix for hormone quantification can be limited by the low hormone 
concentrations present in saliva and by the limited possibility to standardise sample collection as the 
collection is carried out by patients on their own. However, LC-MS/MS provides the sensitivity and 
specificity to overcome these limitations 
21, 22
. 
We performed a strict validation of the developed assay that guarantees its accurate, precise and 
reproducible performance. The assay was demonstrated to be highly selective and no interference with 
other common natural steroids and steroidal drugs was detected. There is no significant ion suppression 
and the assay demonstrates excellent recovery, intra- and inter-assay precision and linearity. The high bias 
between measured and theoretical concentrations when diluting samples suggests that dilution of a sample 
with PBS/BSA prior to extraction cannot be applied.  However, given that the highest concentrations 
measured in women during the luteal phase of their menstrual cycle (Figure 2) are within the linear range 
of our standard curve, dilutions are generally not required. The sample remains stable after extraction and 
reconstitution, which facilitates its implementation in the workflows of a clinical laboratory.  
We have successfully applied the LC-MS/MS assay to measure salivary progesterone concentrations in 
nine healthy female volunteers during their physiological menstrual cycle (Figure 2). Seven out of nine 
participants showed the expected increase in progesterone concentrations during the luteal phase 
indicative of ovulation at mid-cycle 
1
. The determined maximum concentrations of up to over 500 pmol/L 
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confirmed the correct choice of the working standard concentrations. The assay allows for the monitoring 
of physiological alterations of progesterone concentrations using a non-invasive sampling technique and 
high-throughput analysis demonstrating clinical applicability for long-term monitoring. The tendency for 
an increase of salivary progesterone in the morning hours (Figure 2B) is consistent with the awakening 
response for progesterone established for a large cohort of women using a radioimmunoassay for the 
measurement of salivary progesterone 
30
. However, we would like to emphasize that, due to the small 
number of participants, the presented data of salivary progesterone concentrations for healthy women does 
not allow conclusions about reference ranges and natural variations. 
The presented LC-MS/MS method allows the robust quantification of salivary progesterone without the 
risk of interference with related compounds, as opposed to immunoassays. In combination with the self-
administered sampling of saliva and the high-throughput of the assay, this gives the opportunity to 
establish reliable reference ranges from large populations to assess luteal and placental functions. In 
addition, the availability of this high-throughput salivary progesterone assay will help to explore the role 
of progesterone in disorders of steroidogenesis with increased progesterone levels, specifically the 
monitoring of steroid replacement therapy in congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency, in whom increased serum progesterone indicates insufficient replacement 
31, 32
, with increased 
progesterone often adversely impacting the ability of these patients to conceive 
33
.    
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Table 1: Summary of the analytical performance validation. Criteria were assessed at three different 
concentrations within the standard curve (80, 800, 3200 pmol/L).  
Validation criteria Parameter assessed Results 
Ion suppression % Peak area matrix vs. water (n=6) 93.2 ± 8.1% 
Recovery % Concentration matrix vs. 50% methanol (n=5) 90.9 ± 2.8 % 
Linearity R
2
 of serial dilutions (n=3) 0.997 ± 0.001 
Intra-assay imprecision CV (n=10) 
Bias 
<11.4% 
<8.6% 
Inter-assay imprecision CV (n=10) 
Bias  
<10.5% 
< 10.9% 
LLOQ CV and bias < 20% (n=10) 20 pmol/L 
Post-extraction stability at 4 °C  Bias of duplicate measurements (n=24) -1.9-5.4% 
Carry over Peak area in subsequent blank sample < 0.38% 
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Figures and figure legends  
 
 
Figure 1: Chromatogram of a saliva sample containing progesterone. Progesterone (upper panel) and 
the internal standard D9-progesterone (lower panel) co-elute as distinct peaks with no interfering signals. 
Quantifier transitions are shown and the fragmentation is indicated. 
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Figure 2: Menstrual and diurnal variations of salivary progesterone in women with a regular 
menstrual cycle. (A) Variations of morning salivary progesterone over the menstrual cycle (n=9). 
Samples were collected daily on days 1-7 and 18-24 between awakening and 10:00 a.m. (B) Diurnal 
variation of salivary progesterone during luteal phase (days 19-22) in women with a luteal progesterone 
surge (n=7).  Samples were collected within +/- 30 minutes of the indicated time points. 
